Cognitive dysfunction in mitochondrial disorders

Abstract

Among the various central nervous system (CNS) manifestations of mitochondrial disorders (MIDs), cognitive impairment is increasingly recognized and diagnosed (mitochondrial cognitive dysfunction). Aim of the review was to summarize recent findings concerning the aetiology, pathogenesis, diagnosis and treatment of cognitive decline in MIDs. Among syndromic MIDs due to mitochondrial DNA (mtDNA) mutations, cognitive impairment occurs in patients with mitochondrial encephalopathy, lactic acidosis and stroke-like episodes syndrome, myoclonus epilepsy with ragged-red fibres syndrome, mitochondrial chronic progressive external ophthalmoplegia, Kearns-Sayre syndrome, neuropathy, ataxia and retinitis pigmentosa syndrome and maternally inherited diabetes and deafness. Among syndromic MIDs due to nuclear DNA (nDNA) mutations, cognitive decline has been reported in myo-neuro-gastro-intestinal encephalopathy, mitochondrial recessive ataxia syndrome, spinocerebellar ataxia with encephalopathy, Mohr-Tranebjaerg syndrome, leuko-encephalopathy; brain and spinal cord involvement and lactic acidosis, CMT2, Wolfram syndrome, Wolf-Hirschhorn syndrome and Leigh syndrome. In addition to syndromic MIDs, a large number of non-syndromic MIDs due to mtDNA as well as nDNA mutations have been reported, which present with cognitive impairment as the sole or one among several other CNS manifestations of a MID. Delineation of mitochondrial cognitive impairment from other types of cognitive impairment is essential to guide the optimal management of these patients. Treatment of mitochondrial cognitive impairment is largely limited to symptomatic and supportive measures. Cognitive impairment may be a CNS manifestation of syndromic as well as non-syndromic MIDs. Correct diagnosis of mitochondrial cognitive impairment is a prerequisite for the optimal management of these patients.

Pregnancy, sex and hormonal factors in multiple sclerosis

“…A challenge for all MS registry initiatives is to combine datasets to generate large international cohorts, with shared demographic and clinical information. 98,99 …”

Mitochondrial Disease in Childhood: Nuclear Encoded

“…The cognitive decline is often seen in a setting of epilepsy, stroke-like episodes, weakness, spasticity, movement disorders, ataxia, weakness, and migraine headache. Neuroimaging may reveal global cerebral atrophy, basal ganglia calcifications or areas of hyperintensity in the basal ganglia or white matter [106]. Cognitive decline may be seen in MNGIE; POLG-related disorders; PEO owing to mutations in Twinkle, TK2, or ANT1; LBSL; CMT type 2; Leigh syndrome (SURF1); diabetes insipidus, diabetes mellitus, optic atrophy, deafness (Wolfram syndrome); and MohrTranebjaerg (DDP1: deafness and dystonia syndrome) [107].…”

Inhibiting the Mitochondrial Calcium Uniporter during Development Impairs Memory in Adult Drosophila

“…Moreover, deficits in cognition are associated with many mitochondrial protein mutations (Finsterer, 2012), and many neurodegenerative disorders have associated mitochondrial defects (Schon and Przedborski, 2011). Experiments performed in rhesus monkeys demonstrated that the number of normal, oblong-shaped mitochondria (as opposed to ‘donut-shaped’ malformed ones) directly correlates with synapse size and working memory test scores, thus suggesting that mitochondrial functions are important for learning and memory processes (Hara et al, 2014, 2016).…”